Abstract Library

#3304 Ga-68/Lu-177 octreotate theranostic paradigm in metastatic Merkel cell carcinoma

Introduction: Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine tumor with poor survival and significant propensity for metastasising. MCC is normally characterised by an up-regulation of somatostatin receptors (SSTR) which introduces the possibility for a targeted treatment approach using peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lenzo N

Authors: Falzone N, Meyrick D, Lee B, Lenzo N,

Keywords: peptide receptor radionuclide therapy, Merkel cell carcinoma, Lu-177 octreotate, Ac-225 octreotate,

#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery

Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, Elio G,

Keywords: Functioning pancreatic neuroendocrine tumors, pancreatic surgery,

#3031 Primitive Peripheral Neuroectodermal Tumor: Case Report

Introduction: Primitive neuroectodermal tumors belong to the family of Ewing sarcomatous tumors, all derived from the same stem cell. The cells of the neural crest are believed to be at the origin of these tumors. The predilection sites of these sarcomas are para-vertebral region, chest wall and the distal ends. The positive diagnosis of primary neuroectodermal tumors requires the contribution of histopathology, immunohistochemistry and cytogenetics.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ikram B, Soumeya G,

Keywords: Primitive neuroectodermal tumor, primary, peripheral, pPNET, CD99, surgery, chemotherapy,

#2103 Neuroendocrine Tumors in the Chilean Population

Introduction: In recent years, neuroendocrine tumors (NETs) have shown a significant raise in prevalence and incidence. However this observation needs to be accurately quantified using reliable epidemiological databases.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Carrillo D

Authors: Carrillo D, Valenzuela Y, Pinto M, Retamal I, Balmaceda C,

Keywords: Neuroendocrine, Carcinoid, Registry, 5-Hydroxyindoleacetic acid, Serotonin, Chromogranin A,

#1813 Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response

Introduction: Sunitinib prolongs PFS in pNET; RECIST defined-partial responses (PR; ≥30% decrease) are low.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lamarca A

Authors: Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz H,

Keywords: sunitinib, RECIST, cut-off,